(b)(4).In response to an fda inspection ((b)(4)), carefusion 2200 initiated a capa investigation (capa is (b)(4)).As part of the capa, a retrospective review of the complaints for "debris" and "contamination" for applicable devices was conducted.It was determined that this report necessitates submission as a medical device report (mdr).Evaluation summary: one (1) unopened sample was provided for evaluation.Evaluation of the complaint sample confirmed the presence of a loose flake of silicone adhesive on the exterior wall of the chamber.It has been identified that this failure mode is not an isolated event.A thorough review of applicable manufacturing procedures identified a specific manufacturing step that may have contributed to the reported failure mode.A device history record (dhr) review, raw material history files, and the sterilization batch records for the listed manufacturing lots showed no recorded quality problems or rejections related to this incident.Based on the investigation results, the root cause for this failure mode was identified as a process error (loose silicone adhesive generated during the manufacturing of the affected unit within lot 0000478616), which generated the confirmed failure mode of a loose flake of silicone adhesive on the external surface of the shunt chamber.The manufacturing plant has also initiated a capa investigation (b)(4)) to address the reported issue.All corrective and preventive actions (including manufacturing and quality plan improvements) will be implemented per the capa.
|